Tag Archives: BTCY

Top Medical Stocks To Buy For 2018

Boston, MA, based Investment company North Tide Capital, Llc buys Impax Laboratories, Allergan PLC, Accuray, sells Community Health Systems, Valeant Pharmaceuticals International, Mylan NV, Perrigo Co PLC, Select Medical Holdings during the 3-months ended 2016-12-31, according to the most recent filings of the investment company, North Tide Capital, Llc. As of 2016-12-31, North Tide Capital, Llc owns 14 stocks with a total value of $483 million. These are the details of the buys and sells.

New Purchases: IPXL, AGN, ARAY, Added Positions: MYGN, KND, Reduced Positions: MYL, SEM, SVU, GILD, LPNT, Sold Out: CYH, VRX, PRGO, AFAM, ADUS,

For the details of NORTH TIDE CAPITAL, LLC’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=NORTH+TIDE+CAPITAL%2C+LLC

These are the top 5 holdings of NORTH TIDE CAPITAL, LLCSelect Medical Holdings Corp (SEM) – 10,000,000 shares, 27.46% of the total portfolio. Shares reduced by 23.66%SUPERVALU Inc (SVU) – 18,469,921 shares, 17.87% of the total portfolio. Shares reduced by 24.61%Gilead Sciences Inc (GILD) – 500,000 shares, 7.42% of the total portfolio. Shares reduced by 37.5%Kindred Healthcare Inc (KND) – 4,250,000 shares, 6.91% of the total portfolio. Shares added by 6.25%Syneron Medical Ltd (ELOS) – 3,500,000 shares, 6.09% of the total portfolio. New Purchase: Impax Laboratories Inc (IPXL)

North Tide Capital, Llc initiated holdings in Impax Laboratories Inc. The purchase prices were between $12.75 and $24.23, with an estimated average price of $17.1. The stock is now traded at around $9.15. The impact to the portfolio due to this purchase was 5.49%. The holdings were 2,000,000 shares as of 2016-12-31.

Top Medical Stocks To Buy For 2018: Biotricity (BTCY)

Advisors’ Opinion:

  • [By Robert J. Smith]

    Biotricity (OTCBB: BTCY) is a comer in the rapidly growing medical device market and is a small cap to take notice of. Driving this lucrative market are; IoT-driven device connectivity, governmental pressure to cut healthcare costs, escalating hospital costs, a need to reduce hospital readmission rates, an aging population, and a high rate of people with chronic disease. The largest factor driving this market is the rapidly growing rate of those afflicted with chronic disease.

  • [By Peter Graham]

    Sandhill.com recently interviewed the chairman, CEO and founder Waqaas Al-Siddiq small cap wearables stock Biotricity (OTCQB: BTCY) about how wearables benefit patients, integrate into healthcare systems and improve treatment compliance as well as how the cloud and the Internet of Things impact the medical wearables space. biotricitys is a medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. biotricitys R&D focuses on the preventative healthcare market, with a vision of putting health management into the hands of the individual by supporting the self-management of critical and chronic conditions.

  • [By Matthew Briar]

    Ever heard the term ‘mHealth’? Or, maybe you’ve heard it by the full-length (and less hip) characterization mobile health. Regardless of what you call it, it’s the same … it’s the Q&D way to describe the new era of healthcare and medical equipment that operates outside of a hospital or clinic, and doesn’t require any wires to function. It’s the new way of taking care of patients, and more important, it’s a huge market. The mHealth market is projected to grow from $13.6 billion in 2015 to $49.1 billion by 2020, as the premise and technology hits a critical mass.

    It’s an undertow – a paradigm shift – that favors lots of small cap stocks, but perhaps none as much as Biotricity Inc (OTCMKTS:BTCY).

    Biotricity isn’t a household name. It may be soon, however. It’s the developer of two different but related wearable, 24/7 heart monitoring technologies. The device called bioflux is for use by caregivers in a clinical setting, remotely transmitting detailed information about the heart’s functioning which can then be analyzed by caregivers. The device known as biolife serves individuals outside of a clinical setting, largely doing the same chore. The advantage of the technology is mobility, without sacrificing accuracy.

    The device furthest along the development path is bioflux. The company recently filed a 510k request with the FDA for its bioflux technology (the 510k path is for medical devices rather than drugs, and as such doesn’t require a lot of regulatory deliberation), and has heard back from the FDA about a key part of the device already – it got the green light. Another arm of the FDA must look at other aspects of the device.

    The two devices utilize the same basic technology, but are clearly addressing different markets.

    It must also be noted that the ECG monitoring software found in a bioflux has been approved by the FDA in the past and is already rather standard technology for ECG monitoring equipment in hospitals and

Top Medical Stocks To Buy For 2018: Merrimack Pharmaceuticals, Inc.(MACK)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
    Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
    Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
    Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
    Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
    Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
    Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
    Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
    Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
    BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
    Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
    Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than
  • [By Paul Ausick]

    Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) dropped nearly 11% on Tuesday to post a new 52-week low of $3.30 after closing at $3.67 on Monday. Volume was more than 3 times the daily average of about 3.7 million shares. The stock’s 52-week high is $9.02 The company said Tuesday that it has sold some of its cancer drugs to Ipsen for $1 billion.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Aceto Corporation (NASDAQ: ACET) fell 41.9 percent to $4.30 in pre-market trading. ACETO board disclosed that it is taking proactive steps to address business and financial challenges. Canaccord Genuity downgraded Aceto from Buy to Sell.
    Helios and Matheson Analytics Inc. (NASDAQ: HMNY) fell 25.3 percent to $2.86 in pre-market trading after reporting an ATM offering of $150 million.
    Pier 1 Imports, Inc. (NYSE: PIR) fell 17.4 percent to $2.86 in pre-market trading after reporting a fourth quarter sales miss. Comps were down 7.5 percent in the quarter.
    Sleep Number Corporation (NASDAQ: SNBR) fell 12.4 percent to $32.00 in pre-market trading following a first quarter earnings miss.
    Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) fell 10.2 percent to $11.90 in pre-market trading on news of $125 million convertible debt offering.
    Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares fell 8 percent to $8.02 in pre-market trading after dropping 2.02 percent on Wednesday.
    Exponent, Inc. (NASDAQ: EXPO) shares fell 5.6 percent to $80 in pre-market trading.
    Lumentum Holdings Inc. (NASDAQ: LITE) shares fell 4.8 percent to $60.00 in pre-market trading after rising 1.78 percent on Wednesday.
    vTv Therapeutics Inc. (NASDAQ: VTVT) fell 4.6 percent to $2.10 in pre-market trading after surging 84.87 percent on Wednesday.
    Taiwan Semiconductor Manufacturing Company Limited (NYSE: TSM) shares fell 4.5 percent to $40.07 in pre-market trading after the company reported Q1 results.
    Align Technology, Inc.. (NASDAQ: ALGN) fell 3.5 percent to $267.40 in pre-market trading after rising 1.61 percent on Wednesday.
    Transocean Ltd. (NYSE: RIG) shares fell 3.5 percent to $12 in pre-market trading after the company issued quarterly fleet status report.
    GoPro, Inc. (NASDAQ: GPRO) fell 3.2 percent to $4.90 in pre-market trading.
    Unilever PLC (NYSE: UL) fell 2.6 percent to $54.73 in pre-market

Top Medical Stocks To Buy For 2018: L.B. Foster Company(FSTR)

Advisors’ Opinion:

  • [By Lee Jackson]

    The L.B. Foster Co. (NASDAQ: FSTR) had one of itsdirectors adding to a position last week. Legion Partners bought 72,301 shares of the transportation and energy infrastructure company at prices between $12.27 and $13.07. The total for the purchase came in right at $1 million. The shares closed Friday at $13.30, in a 52-week range of$9.25 to $20.77. The consensus price target is $15.00.

  • [By Lisa Levin]

    Friday afternoon, the basic materials sector proved to be a source of strength for the market. Leading the sector was strength from Intrepid Potash, Inc. (NYSE: IPI) and L.B. Foster Co (NASDAQ: FSTR).

  • [By Lisa Levin]

    Wednesday afternoon, basic materials shares gained by 1.74 percent. Meanwhile, top gainers in the sector included Intrepid Potash, Inc. (NYSE: IPI), and L.B. Foster Co (NASDAQ: FSTR).

Top Medical Stocks To Buy For 2018: American Express Company(AXP)

Advisors’ Opinion:

  • [By Paul Ausick]

    American Express Co. (NYSE: AXP) traded up 0.57% at $88.70. The stock’s 52-week range is $59.50 to $89.38. Volume was about half the daily average of around 3.2 million. The company had no specific news Tuesday.

  • [By Cooper Creagan]

    Since then, the money spent using prepaid cards has nearly doubled, as big players like Wal-Mart Stores Inc. (NYSE: WMT) and American Express Co. (NYSE: AXP) have entered the game with the prepaid Bluebird card.

  • [By Garrett Baldwin]

    The Ripple coin topped $0.23 after a 10% surge during Thursday trading. The price surged after credit card giant American Express Co. (NYSE: AXP) announced it has established a payments corridor between the United States and the United Kingdom using Ripple’s technology.

  • [By Paul Ausick]

    American Express Co. (NYSE: AXP) traded up 1.41% at $99.36. The stock’s 52-week range is $75.51 to $102.39. Volume was about 10% above the daily average of around 3.4 million shares. The company had no news Wednesday.

  • [By Chris Lange]

    American Express Co. (NYSE: AXP) will share its latest quarterly earnings on Wednesday. The consensus estimates call for $1.48 in EPS and $8.29 billion in revenue. Shares ended last week at $92.86, in a 52-week range of $59.78 to $92.92. The consensus analyst target is $89.91.

  • [By Paul Ausick]

    American Express Co. (NYSE: AXP) traded down 0.64% at $73.89. The stock’s 52-week range is $50.27 to $75.74. Volume was less than half the daily average of around 4.7 million shares. The company had no specific news.

Best Energy Stocks To Invest In Right Now

Gasoline demand at the pump hit a record level in March thats typically seen during the summer driving season, motoring and leisure travel membership organization AAA said Monday.

The Energy Information Administration data show that U.S. motor gasoline product supplied, which offers a gauge of demand, rose to 9.64 million barrels a day for week ended March 9, from roughly 9.28 million barrels a day a week earlier.

Best Energy Stocks To Invest In Right Now: Minerva Neurosciences, Inc(NERV)

Advisors’ Opinion:

  • [By Lisa Levin]

    Minerva Neurosciences Inc (NASDAQ: NERV) shares shot up 194 percent to $10.39 after the company revealed positive top line results from a prospective Phase IIb, 12-week, randomized, double-blind, placebo-controlled parallel clinical study evaluating the efficacy, safety and tolerability of MIN-101 in patients with negative symptoms of schizophrenia.

Best Energy Stocks To Invest In Right Now: Cray Inc(CRAY)

Advisors’ Opinion:

  • [By Jim Robertson]

    Cray Inc. (CRAY) has been one of those feast or famine small caps that have either made traders and investors a lot of money in recent years – or simply frustrated those who’ve held it for quite some time. However, at this point we think CRAY offers an attractive risk/reward opportunity on a long-term basis for investors interested in exposure to big data analytics and specifically super-computing – a growing need for large enterprise and institutions all over the world

  • [By Peter Graham]

    The Q4 2016 earnings report for small capsupercomputer stock Cray Inc (NASDAQ: CRAY) is scheduled forafter the market closes onWednesday (February 8th). Back in 2012, Cray Inc was inour SmallCap Network Elite Opportunity (SCN EO) portfolioasa potentially goodlow risk longer-term play as shares were trading at the $12 level and eventually hit $40+ per share before coming back down to earth last year.

  • [By Lisa Levin]

    Tuesday afternoon, the technology sector proved to be a source of strength for the market. Leading the sector was strength from Cray Inc. (NASDAQ: CRAY) and Mellanox Technologies, Ltd. (NASDAQ: MLNX).

  • [By Giulio Prisco]

    Microsoft (NSDQ:MSFT), supercomputer maker Cray (NSDQ:CRAY), and the Swiss National Supercomputing Centre (CSCS), a world-class scientific computing center, announced the results of a deep learning collaboration that expands the horizons of running Artificial Intelligence (AI), Machine Learning (ML), and in particular Deep Learning (an especially promising branch of ML) applications, using Microsoft software and Cray supercomputers.

Best Energy Stocks To Invest In Right Now: Biotricity (BTCY)

Advisors’ Opinion:

  • [By Peter Graham]

    Sandhill.com recently interviewed the chairman, CEO and founder Waqaas Al-Siddiq small cap wearables stock Biotricity (OTCQB: BTCY) about how wearables benefit patients, integrate into healthcare systems and improve treatment compliance as well as how the cloud and the Internet of Things impact the medical wearables space. biotricitys is a medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. biotricitys R&D focuses on the preventative healthcare market, with a vision of putting health management into the hands of the individual by supporting the self-management of critical and chronic conditions.

  • [By James E. Brumley]

    When an investor thinks of stocks in the cardio-monitoring arena, names like General Electric Company (NYSE:GE) and Medtronic PLC (NYSE:MDT) tend to surface first. And well they should. Medtronic is the largest name dedicated solely to equipment that tells doctors and nurses how well a patient’s heart is functioning, while GE Healthcare smartly leverages the name of its parent company’s recognizable name to win market share in the medical equipment space.

    General Electric and Medtronic aren’t the only names in town, however, and certainly not the top prospects for an investor seeking out a fresh, undiscovered growth opportunity. That honor arguably belongs to an up-and-coming small cap outfit called Biotricity Inc. (OTCMKTS:BTCY), which is nearing its first-ever revenue.

    Don’t look for a Biotricity product quite yet, as they’re not on the market. Consumers as well as investors will want to keep their eyes and ears open for two of them soon though, however, with one of those devices being a high-precision, FDA-approved instrument for use by healthcare workers in a clinical setting. The other device is a consumer-oriented version of the same technology, giving BTCY access to not just one but two crucial markets. Even more recently Biotricity reported it was opening up its development pipeline to the fetal monitoring and sleep apnea markets. Heart-monitoring is the near-term venture, though.

    The two products are called biotricity and biolife (neither moniker is supposed to be capitalized). The latter is a wireless, remote consumer-oriented heart rate and activity monitoring device, and the former is a clinical-grade monitoring device… also wireless and remotely operated/monitored.

    Bioflux is only available by prescription. The bioflux hardware includes an ECG (heart-rhythm) monitoring device, software, and if desired, service from a monitoring lab that performs remote diagnostic monitoring for up to 30 consecutive days at a time. It

  • [By Matthew Briar]

    Biotricity Inc (OTCMKTS:BTCY) announced on Tuesday morning it was teaming up with Global to Local (G2L) to develop remote monitoring solutions that not only work, but serve the underserved (medically speaking) community. This partnership is of particular interest to current and would-be BTCY investors, as it will likely validate the crux of the work the company has done thus far.

    Biotricity is the developer of two different though related technologies. One is called bioflux, and the other is called biolife. Both are heart-monitoring devices… the former for use by caregivers in a clinical setting, while the latter is for use by individuals outside of a clinical setting. Neither is on the market yet, but both are projected to be on the market next year. The company recently filed a 510k request with the FDA for its bioflux technology (the 510k path is for medical devices rather than drugs, and as such doesn’t require a lot of regulatory deliberation), and has heard back from the FDA about a key part of the device already – it got the green light. Another arm of the FDA must look at other aspects of the device.

    The technology is unique, in that it not only provides stunningly accurate detailed information about a patient’s heart function, but it constantly feeds that data – remotely – to a caregiver and monitor that can make good use of that data. In August the company announced AT&T Inc. (NYSE:T) would be handling the wireless (cellular) connectivity between clinics and patients’ bioflux devices.

    It’s a breakthrough, for many reasons, not the least of which is that remote monitoring lowers overall healthcare costs for those patients, and ultimately, for insurers.

    The hardware is not yet available on a commercial basis, but it is being tested in a clinical setting. The Global to Local partnership will be another field test of sorts, validating the work Biotricity has performed on the R&D front.

    The organization says

  • [By Peter Graham]

    On the other hand, small cap wearables stock Biotricity (OTCQB: BTCY)is a different wearables play as theCompanys mission is to revolutionize chronic care management by developing innovative solutions that bridge the gap between diagnostic care and disease management. A medical technology company, Biotricity is focused on delivering innovative, remote biometric monitoring solutions to the healthcare and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricitys R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The Company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system.

stock valuation

Small cap poultry processing stock Sanderson Farms, Inc (NASDAQ: SAFM) reported Q2 2017 earnings before the market opened this morning as shares still have elevated short interest of 27.73% according to Highshortinterest.comdue in part to fears over bird flu that have probably subsided. Net sales were $802.0 million versus $692.1million while net income was $66.9 million versus net income of $47.6 million. Overall market prices for poultry products were higher during the second quarter compared with the same period last year while market prices for chicken products sold to retail grocery store customers remained relatively strong during the quarter and continue to reflect good demand. The earnings release noted:

Compared with the second fiscal quarter of 2016, boneless breast meat market prices were approximately 9.1 percent higher, the average market price for bulk leg quarters increased approximately 17.2 percent, and jumbo wing market prices were higher by 5.1 percent. The Company’s average feed costs per pound of poultry products processed were essentially flat when compared with the second quarter of fiscal 2016, while prices paid for corn and soybean meal, the Company’s primary feed ingredients, decreased 0.4 percent and increased 15.0 percent, respectively, compared with the second quarter of fiscal 2016. The Company’s feed costs per pound processed were affected by changes in feed formulation and improved broiler performance.

stock valuation: Rockwell Automation, Inc.(ROK)

Advisors’ Opinion:

  • [By Lee Jackson]

    These companies also reported insider selling last week: Aetna Inc. (NYSE: AET), Cullen/Frost Bankers Inc. (NYSE: CFR), Rockwell Automation Inc. (NYSE: ROK), Stamps.com (NASDAQ: STMP) and Western Alliance Bancorporation (NYSE: WAL).

  • [By Lisa Levin]

    Breaking news

    Cisco Systems, Inc. (NASDAQ: CSCO) reported better-than-expected profit for its first quarter on Wednesday.
    Helmerich & Payne, Inc. (NYSE: HP) posted upbeat results for its fourth quarter.
    NetApp Inc. (NASDAQ: NTAP) reported stronger-than-expected results for its second quarter and issued strong Q3 guidance.
    Emerson Electric Co. (NYSE: EMR) proposed to acquire Rockwell Automation (NYSE: ROK) for $225 per share in cash and stock.

  • [By Paul Ausick]

    Blaming the unwillingness of its target even to discuss a buyout, Emerson Electric Co. (NYSE: EMR) on Tuesday announced that it has withdrawn its unsolicited offer to acquire Rockwell Automation Inc. (NYSE: ROK) for $225 a share in a deal valued at nearly $30 billion.

  • [By Ben Levisohn]

    Bernstein’s Steven Winoker looks back at 2016 for the industrial stocks he covers–Ingersoll-Rand (IR), Rockwell Automation (ROK), Eaton (ETN), and General Electric (GE) among them–and contemplates what 2017 might hold:

stock valuation: Eagle Bancorp, Inc.(EGBN)

Advisors’ Opinion:

  • [By Paul Ausick]

    Eagle Bancorp Inc. (NASDAQ: EGBN) dropped 28% Friday to post a new 52-week low of $47.65 after closing at $66.15 on Thursday. The stock’s 52-week high is $69.80. Volume of around 3.6 million was more than three times the daily average. The bank holding company had no specific news Friday.

  • [By Lisa Levin]

    On Monday, the financial sector proved to be a source of strength for the market. Leading the sector was strength from Eagle Bancorp, Inc. (NASDAQ: EGBN) and BankUnited (NYSE: BKU).

stock valuation: Biotricity (BTCY)

Advisors’ Opinion:

  • [By Peter Graham]

    Finally, small cap Biotricity (OTCQB: BTCY)is an entirely different wearables play as its a medical technology company whos mission is to revolutionize chronic care management by developing innovative solutions that bridge the gap between diagnostic care and disease management. More specifically, biotricity is focused on delivering innovative, remote biometric monitoring solutions to the healthcare and consumer markets -including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. biotricitys R&D is focused on the preventative healthcare market as the company aims to support the self-management of critical and chronic conditions to ease the growing burden on the healthcare system.

  • [By James E. Brumley]

    Biotricity Inc (OTCMKTS:BTCY), a developer of remote health-monitoring devices, reminded us not so gently today that while it’s waiting on the last of the necessary approvals from the FDA for its hardware, it’s still moving the ball downfield (so to speak). That is to say, it’s already lined up a manufacturer for its so-called Bioflux cardiac monitor for when the last green light is given, and it’s a good one…. Providence Enterprise . That’s the same company that makes some of the equipment and goods within your sight right now.

    Biotricity is the name behind two pieces of technology, both of which are nearing the end of their development. One is the aforementioned Bioflux, and the other is called biolife…. the latter for use by individuals outside of a clinical setting. Neither is on the market yet, but both are projected to be on the market this year. In fact, the company demonstrated its IoT-connected bioflux at this year’s Mobile World Congress (MWC) 2017 in Barcelona, Spain a couple of weeks ago. The crowd liked what it saw.

    The marketable version of the device isn’t available yet; it’s still going through the approval process. The company recently filed a 510k request with the FDA for its bioflux technology (the 510k path is for medical devices rather than drugs, and as such doesn’t require a lot of regulatory deliberation), and has heard back from the FDA about a key part of the device already – it got the green light. Another arm of the FDA must look at other aspects of the device, and that portion of the review takes longer.

    Still, the company is rightfully optimistic, so much so that it’s already lined up a company to manufacture the Bioflux device once the final approval and final specs are in. That company is Providence Enterprise, which has a long history in making drug delivery and diagnostic equipment, as well as plenty of experience making electronics. The Bioflux will be a blend of both capabilities.

    It’s in

  • [By Robert J. Smith]

    Biotricity (OTCBB: BTCY) is a comer in the rapidly growing medical device market and is a small cap to take notice of. Driving this lucrative market are; IoT-driven device connectivity, governmental pressure to cut healthcare costs, escalating hospital costs, a need to reduce hospital readmission rates, an aging population, and a high rate of people with chronic disease. The largest factor driving this market is the rapidly growing rate of those afflicted with chronic disease.

  • [By Matthew Briar]

    Biotricity Inc (OTCMKTS:BTCY) announced on Tuesday morning it was teaming up with Global to Local (G2L) to develop remote monitoring solutions that not only work, but serve the underserved (medically speaking) community. This partnership is of particular interest to current and would-be BTCY investors, as it will likely validate the crux of the work the company has done thus far.

    Biotricity is the developer of two different though related technologies. One is called bioflux, and the other is called biolife. Both are heart-monitoring devices… the former for use by caregivers in a clinical setting, while the latter is for use by individuals outside of a clinical setting. Neither is on the market yet, but both are projected to be on the market next year. The company recently filed a 510k request with the FDA for its bioflux technology (the 510k path is for medical devices rather than drugs, and as such doesn’t require a lot of regulatory deliberation), and has heard back from the FDA about a key part of the device already – it got the green light. Another arm of the FDA must look at other aspects of the device.

    The technology is unique, in that it not only provides stunningly accurate detailed information about a patient’s heart function, but it constantly feeds that data – remotely – to a caregiver and monitor that can make good use of that data. In August the company announced AT&T Inc. (NYSE:T) would be handling the wireless (cellular) connectivity between clinics and patients’ bioflux devices.

    It’s a breakthrough, for many reasons, not the least of which is that remote monitoring lowers overall healthcare costs for those patients, and ultimately, for insurers.

    The hardware is not yet available on a commercial basis, but it is being tested in a clinical setting. The Global to Local partnership will be another field test of sorts, validating the work Biotricity has performed on the R&D front.

    The organization says

  • [By James E. Brumley]

    While the economy’s natural — and recurring — cycles favor different kinds of stocks at different times, not every great trend is necessarily a cyclical one. Sometimes, a trend is rooted in a technological development that changes cultural norms. The advent of the smartphone, for example, has made constant connectivity to the world around part of how we live our daily lives.

    These mega-trends present tremendous opportunities for investors too, provided they’re savvy enough to see them coming and play them the right way.

    One such mega-trend newly underway right now is the proliferation of wearables… devices that meld clothing (often a wrist-worn device) and technology to perform a function that couldn’t be performed otherwise. Much of the same technology that made the smartphone possible are now ushering in wearables.

    It’s not been a smooth beginning. however.

    While the buzz was strong and expectations reached a peak two years ago when Fitbit Inc (NYSE:FIT) was all the rage and in the wake of its IPO, the company’s growth wasn’t to be sustained. The company is struggling to muster any growth now, and FIT shares have fallen to a tenth of their value seen in late-2015, when the euphoria was strongest.

    Fitbit’s slowdown has been mirrored by other companies in the space. The wearables market only grew 3.1% in Q3 of 2016.

    On the flipside, while the debacle of Fitbit — the wearable industry’s iconic company — has been a painful, it’s also been a learning experience. And, it’s not as if the slowdown is unfurling without the wearables market never reaching a respectable size. International Data Corporation estimates were 23 million ‘wearables’ delivered in the third quarter of last year alone.

    Moreover, the fizzling of the market hasn’t turned into a reason to swear off wearables as an investment opportunity… quite the opposite, actually. It’s just now become considerably clearer what consumers want an

stock valuation: Computer Programs and Systems Inc.(CPSI)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Computer Programs & Systems, Inc. (NASDAQ: CPSI) were down 31 percent to $27.00 after the company posted weaker-than-expected Q2 results.

stock valuation: Roadrunner Transportation Systems, Inc(RRTS)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Tuesday was another down day for the Dow Jones Industrials, which fell more than 100 points to drop further below the 20,000 level. But broader market measures were mixed, and the Nasdaq Composite even managed to gain ground. Continued uncertainty about the impact of new policies from the U.S. federal government have kept markets a bit turbulent, and the beginning of a two-day meeting of the Federal Reserve’s Open Market Committee could set the tone for monetary policy in 2017. Some stocks had bad news that sent them lower today, and among the worst performers were Seadrill (NYSE:SDRL), Roadrunner Transportation Systems (NYSE:RRTS), and Tempur Sealy International (NYSE:TPX). Below, we’ll look more closely at these stocks to tell you why they did so poorly.

stock valuation: United States Steel Corporation(X)

Advisors’ Opinion:

  • [By Shanthi Rexaline]

    Even as there is a scramble toward achieving $1 trillion market cap, Benzinga looked at United States Steel Corporation (NYSE: X), which was the first company ever to be capitalized at over $1 trillion. The history of the steel maker is a checkered one, and over the years, it has lost its shine and appeal and is currently looking a pale shadow of its old self.

  • [By Lee Jackson]

    These companies also reported insider buying last week: Apache Corp. (NYSE: APA), Halliburton Co. (NYSE: HAL), Revlon Inc. (NYSE: REV), Valeant Pharmaceuticals International Inc. (NYSE: VRX) and U.S. Steel Corp. (NYSE: X).

  • [By Lee Jackson]

    This is the granddaddy of the domestic steel producers and another stock rated Buy at Deutsche Bank.United States Steel Corp. (NYSE: X) is an integrated producer of flat carbon steel and pipe with a total 22million tons of capacity in North America and Slovakia.

  • [By Merrick Weingarten]

    Steel stocks were up big on Tuesday ahead of the Department of Commerce hearing on the Section 232 probe. The DoC is set to come out with more details regarding the impact steel imports has on U.S. national security.

    Stock Movements
    United States Steel Corporation (NYSE: X): Up 5.27 percent. AK Steel Holding Corporation (NYSE: AKS): Up 9.55 percent. Nucor Corporation (NYSE: NUE): Up 3.54 percent. Steel Dynamics, Inc. (NASDAQ: STLD): Up 4.08 percent. Worthington Industries, Inc. (NYSE: WOR): Up 3.29 percent.
    Analyst Commentary

    A Jefferies research analyst suggested a high probability of the DoC institutes more incremental trade defense measures but noted most of the investigation remains unknown going into Wednesday.

stock market trading game

I thought the concept of open innovation was just theory. When a behemoth, Microsoft (NASDAQ:MSFT), just took another step closer to fully embrace openness, I was surprised.

Open innovation is the concept of freely allowing access to knowledge resources and other factors that can benefit a firm. However, this form of innovation can be described as collaborative innovation.

Collaborative innovation allows firms such as Microsoft to pursue innovation outside of its boundaries. According to the article, it appears that Microsoft used to be tightly held. For instance, no one would have expected Microsoft to have Google (NASDAQ:GOOG) (NASDAQ:GOOGL) on its .NET Foundation technical steering committee. This strategic alliance can be beneficial for both firms as the learning and knowledge transfer take place between both companies. Since both companies tend to compete in the same space, the strategic alliance can be considered a form of related diversification, where the synergies between both companies should be realized. The only negative thing to worry about is the size of both companies could hinder the progress if the internal cultures in the alliance do not mesh (I can cite hundreds of academic studies on this paragraph alone, but it will confuse you more than help you).

stock market trading game: Norwegian Cruise Line Holdings Ltd.(NCLH)

Advisors’ Opinion:

  • [By Teresa Rivas]

    Norwegian Cruise Lines (NCLH) was up nearly 7% on Wednesday afternoon, following its fourth-quarter earnings report.

    Norwegian said that it earned 56 cents a share, a penny ahead of analysts’ expectations. Revenue rose 8.5% to $1.13 billion, also squeaking past the $1.11 billion consensus estimate.

    For the full year, Norwegian said it expects to earn between $3.75 and $3.85 a share, with a midpoint a penny above the $3.79 average analyst estimate. It’s first-quarter EPS guidance of 36 cents also came in ahead of the 34-cent consensus.

    Instinet analyst Harry Curtiswrites that after recent missteps, it was “vital” for Norwegian’s forecast to meet expectations but not seem too optimistic, a balancing act he believes the company achieved.

    He reiterated a Buy rating and $52 price target on the stock:

    NCLHs 2017 EPS outlook ($3.75 to $3.85) brackets our forecast ($3.75) and the Streets ($3.79). However, we believe there could be upside to that range, given the positive booking and pricing trends so far this year. We remain positive on the shares of NCLH, which we believe should continue to outperform through 2017.

    Norwegian was recently up 6.8% to $51.49.

  • [By Dan Caplinger]

    The stock market once again proved its resiliency on Wednesday, bouncing back from extensive declines early in the session to recover most of its losses. The Dow Jones Industrials actually managed to post yet another record close with a modest gain, and although other major market benchmarks suffered declines, they weren’t significant. Moreover, some favorable news from certain pockets of the market helped bolster investor confidence. Toll Brothers (NYSE:TOL), Lantheus Holdings (NASDAQ:LNTH), and Norwegian Cruise Line Holdings (NASDAQ:NCLH) were among the top performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so well.

  • [By Ben Levisohn]

    Shares of Carnival have dropped 4.2% to $43.74 at 2:39 p.m. today, while Royal Caribbean Cruise (RCL) has tumbled 5.6% to $66.15, and Norwegian Cruise Line Holdings (NCLH) is off 4.3% at $38.63.

  • [By Monica Gerson]

    Norwegian Cruise Line Holdings Ltd (NASDAQ: NCLH) is expected to report its quarterly earnings at $0.37 per share on revenue of $1.10 billion.

    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is projected to post its quarterly earnings at $2.31 per share on revenue of $338.86 million.

stock market trading game: Kronos Worldwide Inc(KRO)

Advisors’ Opinion:

  • [By Monica Gerson]

    Kronos Worldwide, Inc. (NYSE: KRO) is projected to post a quarterly loss at $0.13 per share on revenue of $308.50 million.

    Energen Corporation (NYSE: EGN) is estimated to post a quarterly loss at $0.67 per share on revenue of $122.91 million.

stock market trading game: Fidelity Southern Corporation(LION)

Advisors’ Opinion:

  • [By Lisa Levin]

    Here is the list of stocks going ex-dividend on Monday.

    AptarGroup, Inc. (NYSE: ATR) – $0.3200 dividend, 1.6780 percent yield. AptarGroup reported weaker-than-expected Q3 results on Thursday.
    Fidelity Southern Corporation (NASDAQ: LION) – $0.1200 dividend, 2.6359 percent yield. The company, based in Atlanta, Georgia, provides financial products and services for customers.
    Apple Hospitality REIT Inc (NYSE: APLE) – $0.1000 dividend, 6.5826 percent yield. Apple Hospitality REIT, based in Richmond, Virginia, operates as a subsidiary of Apple REIT Companies.
    Targa Resources Corp (NYSE: TRGP) – $0.9100 dividend, 7.7299 percent yield. The Houston, Texas-based company provides midstream natura

stock market trading game: Biotricity (BTCY)

Advisors’ Opinion:

  • [By James E. Brumley]

    While the economy’s natural — and recurring — cycles favor different kinds of stocks at different times, not every great trend is necessarily a cyclical one. Sometimes, a trend is rooted in a technological development that changes cultural norms. The advent of the smartphone, for example, has made constant connectivity to the world around part of how we live our daily lives.

    These mega-trends present tremendous opportunities for investors too, provided they’re savvy enough to see them coming and play them the right way.

    One such mega-trend newly underway right now is the proliferation of wearables… devices that meld clothing (often a wrist-worn device) and technology to perform a function that couldn’t be performed otherwise. Much of the same technology that made the smartphone possible are now ushering in wearables.

    It’s not been a smooth beginning. however.

    While the buzz was strong and expectations reached a peak two years ago when Fitbit Inc (NYSE:FIT) was all the rage and in the wake of its IPO, the company’s growth wasn’t to be sustained. The company is struggling to muster any growth now, and FIT shares have fallen to a tenth of their value seen in late-2015, when the euphoria was strongest.

    Fitbit’s slowdown has been mirrored by other companies in the space. The wearables market only grew 3.1% in Q3 of 2016.

    On the flipside, while the debacle of Fitbit — the wearable industry’s iconic company — has been a painful, it’s also been a learning experience. And, it’s not as if the slowdown is unfurling without the wearables market never reaching a respectable size. International Data Corporation estimates were 23 million ‘wearables’ delivered in the third quarter of last year alone.

    Moreover, the fizzling of the market hasn’t turned into a reason to swear off wearables as an investment opportunity… quite the opposite, actually. It’s just now become considerably clearer what consumers want an

  • [By Matthew Briar]

    In October, medical technology developer Biotricity Inc. (OTCMKTS:BTCY) announced part of its heart-monitoring hardware received the necessary 501k clearance from the Food & Drug Administration. It was a not-so-subtle reminder that the company is nearing the end of the R&D journey with its bioflux device, which provides caregivers round-the-clock monitoring of a heart patient’s vital stats. BTCY could have the device on the market within a matter of weeks, putting the organization into a multi-billion dollar market with a platform like no other.

    And yet, heart-monitoring is only going to be a part of what the company does.

    Another news later that same month was a not-so-subtle reminder…. Biotricity Inc. is already eyeing the entry into other markets aside from the cardiac market that would benefit from remote monitoring.

    One has to back-track to the September 29th press release to set the stage. That’s when the company announced it would take the same basic remote-monitoring technology and apply it to fetal monitoring and sleep apnea, at least. The way the PR read left open the possibility to even more medically-related uses.

    For some it may have been a read-it-and-forget-it affair. Lots of companies announce their intentions, and then get around to doing it whenever they feel like it, IF they feel like it. Biotricity wasn’t just blowing smoke though. In October the company announced that its primary development partner — the University of Calgary — and it laid out specific plans to create ‘remote monitoring mobile devices in a number of clinical settings, including peri-operative medicine, maternal/fetal medicine and acute and chronic care medicine in order to facilitate the application of “smart” medical grade wearables to the hospital and out-patient settings.’

    This second mention of the idea suggests it’s going to happen sooner than later, even as the company continues to push bioflux to

  • [By James E. Brumley]

    These are two of the key stumbling blocks Fitbit hit, and the two big stumbling blocks Biotricity Inc (OTCMKTS:BTCY) has completely sidestepped.

    For the unfamiliar, Biotricity is the developer of two different but related wearable, 24/7 heart monitoring technologies. The device called bioflux is for use by caregivers in a clinical setting, remotely transmitting detailed information about the heart’s functioning which can then be analyzed by caregivers. The device known as biolife serves individuals outside of a clinical setting, largely doing the same chore. The advantage of the technology is mobility, without sacrificing accuracy.

  • [By James E. Brumley]

    Biotricity Inc (OTCMKTS:BTCY), a developer of remote health-monitoring devices, reminded us not so gently today that while it’s waiting on the last of the necessary approvals from the FDA for its hardware, it’s still moving the ball downfield (so to speak). That is to say, it’s already lined up a manufacturer for its so-called Bioflux cardiac monitor for when the last green light is given, and it’s a good one…. Providence Enterprise . That’s the same company that makes some of the equipment and goods within your sight right now.

    Biotricity is the name behind two pieces of technology, both of which are nearing the end of their development. One is the aforementioned Bioflux, and the other is called biolife…. the latter for use by individuals outside of a clinical setting. Neither is on the market yet, but both are projected to be on the market this year. In fact, the company demonstrated its IoT-connected bioflux at this year’s Mobile World Congress (MWC) 2017 in Barcelona, Spain a couple of weeks ago. The crowd liked what it saw.

    The marketable version of the device isn’t available yet; it’s still going through the approval process. The company recently filed a 510k request with the FDA for its bioflux technology (the 510k path is for medical devices rather than drugs, and as such doesn’t require a lot of regulatory deliberation), and has heard back from the FDA about a key part of the device already – it got the green light. Another arm of the FDA must look at other aspects of the device, and that portion of the review takes longer.

    Still, the company is rightfully optimistic, so much so that it’s already lined up a company to manufacture the Bioflux device once the final approval and final specs are in. That company is Providence Enterprise, which has a long history in making drug delivery and diagnostic equipment, as well as plenty of experience making electronics. The Bioflux will be a blend of both capabilities.

    It’s in

  • [By Matthew Briar]

    Biotricity Inc (OTCMKTS:BTCY) announced on Tuesday morning it was teaming up with Global to Local (G2L) to develop remote monitoring solutions that not only work, but serve the underserved (medically speaking) community. This partnership is of particular interest to current and would-be BTCY investors, as it will likely validate the crux of the work the company has done thus far.

    Biotricity is the developer of two different though related technologies. One is called bioflux, and the other is called biolife. Both are heart-monitoring devices… the former for use by caregivers in a clinical setting, while the latter is for use by individuals outside of a clinical setting. Neither is on the market yet, but both are projected to be on the market next year. The company recently filed a 510k request with the FDA for its bioflux technology (the 510k path is for medical devices rather than drugs, and as such doesn’t require a lot of regulatory deliberation), and has heard back from the FDA about a key part of the device already – it got the green light. Another arm of the FDA must look at other aspects of the device.

    The technology is unique, in that it not only provides stunningly accurate detailed information about a patient’s heart function, but it constantly feeds that data – remotely – to a caregiver and monitor that can make good use of that data. In August the company announced AT&T Inc. (NYSE:T) would be handling the wireless (cellular) connectivity between clinics and patients’ bioflux devices.

    It’s a breakthrough, for many reasons, not the least of which is that remote monitoring lowers overall healthcare costs for those patients, and ultimately, for insurers.

    The hardware is not yet available on a commercial basis, but it is being tested in a clinical setting. The Global to Local partnership will be another field test of sorts, validating the work Biotricity has performed on the R&D front.

    The organization says

stock market trading game: Tuesday Morning Corp.(TUES)

Advisors’ Opinion:

  • [By Monica Gerson]

    Tuesday Morning (NASDAQ: TUES) shares gained 4.87% to create a new 52-week high of $14.63. Tuesday Morning shares have jumped 110.09% over the past 52 weeks, while the S&P 500 index has gained 18.17% in the same period.

  • [By Peter Graham]

    Small cap closeout home decor retailer Tuesday Morning Corporation (NASDAQ: TUES) reported Q4 and fiscal 2017 earnings before the market opened on Thursday. Q4net sales were $223.6 million versus $222.8 million as the Company’s sales comparison to the prior year is impacted by the net closure of 20 stores during the current fiscal year.Comparable store sales increased 1.8% compared to the same period a year ago, and were comprised of a 2.6% increase in customer transactions, partially offset by a 0.8% decrease in average ticket. The Company operated 731 stores at the end of the fiscal year, which is a decrease of 20 stores from the prior year period.The net loss was $17.3 million versusa net loss of $3.9 million.

stock market screener

The parent company of Sears and Kmart, which has been paring costs and hoarding cash in a bid to survive, said Tuesday that it will put off repaying much of a $500 million loanto help shrink its debt.

Subsidiaries of Sears Holdingnow have a deal that will allow them to pay back $100 million of a $500 million loan in July, the initial date of maturity. But the remaining $400 million will not come due until January, 2018, with Sears having the option to push the maturity date out even further to July of next year.

The iconic retailerhas been taking numerous steps to restore its bottom line, which has suffered amid management stumbles, and a retail landscape full of more nimble retailers and shoppers increasingly more interested in shopping online.

After announcing at the start of the year that it would shutter 150 under performing stores, it has recently added at least 30 more locations to the list. The retailer has also been selling off chunks of its extensive real estate holdings, borrowing money, and even putting some of its cherished brands up for sale.

stock market screener: Biotricity (BTCY)

Advisors’ Opinion:

  • [By Robert J. Smith]

    Biotricity (OTCBB: BTCY) is a comer in the rapidly growing medical device market and is a small cap to take notice of. Driving this lucrative market are; IoT-driven device connectivity, governmental pressure to cut healthcare costs, escalating hospital costs, a need to reduce hospital readmission rates, an aging population, and a high rate of people with chronic disease. The largest factor driving this market is the rapidly growing rate of those afflicted with chronic disease.

  • [By Matthew Briar]

    In October, medical technology developer Biotricity Inc. (OTCMKTS:BTCY) announced part of its heart-monitoring hardware received the necessary 501k clearance from the Food & Drug Administration. It was a not-so-subtle reminder that the company is nearing the end of the R&D journey with its bioflux device, which provides caregivers round-the-clock monitoring of a heart patient’s vital stats. BTCY could have the device on the market within a matter of weeks, putting the organization into a multi-billion dollar market with a platform like no other.

    And yet, heart-monitoring is only going to be a part of what the company does.

    Another news later that same month was a not-so-subtle reminder…. Biotricity Inc. is already eyeing the entry into other markets aside from the cardiac market that would benefit from remote monitoring.

    One has to back-track to the September 29th press release to set the stage. That’s when the company announced it would take the same basic remote-monitoring technology and apply it to fetal monitoring and sleep apnea, at least. The way the PR read left open the possibility to even more medically-related uses.

    For some it may have been a read-it-and-forget-it affair. Lots of companies announce their intentions, and then get around to doing it whenever they feel like it, IF they feel like it. Biotricity wasn’t just blowing smoke though. In October the company announced that its primary development partner — the University of Calgary — and it laid out specific plans to create ‘remote monitoring mobile devices in a number of clinical settings, including peri-operative medicine, maternal/fetal medicine and acute and chronic care medicine in order to facilitate the application of “smart” medical grade wearables to the hospital and out-patient settings.’

    This second mention of the idea suggests it’s going to happen sooner than later, even as the company continues to push bioflux to

  • [By James E. Brumley]

    While the economy’s natural — and recurring — cycles favor different kinds of stocks at different times, not every great trend is necessarily a cyclical one. Sometimes, a trend is rooted in a technological development that changes cultural norms. The advent of the smartphone, for example, has made constant connectivity to the world around part of how we live our daily lives.

    These mega-trends present tremendous opportunities for investors too, provided they’re savvy enough to see them coming and play them the right way.

    One such mega-trend newly underway right now is the proliferation of wearables… devices that meld clothing (often a wrist-worn device) and technology to perform a function that couldn’t be performed otherwise. Much of the same technology that made the smartphone possible are now ushering in wearables.

    It’s not been a smooth beginning. however.

    While the buzz was strong and expectations reached a peak two years ago when Fitbit Inc (NYSE:FIT) was all the rage and in the wake of its IPO, the company’s growth wasn’t to be sustained. The company is struggling to muster any growth now, and FIT shares have fallen to a tenth of their value seen in late-2015, when the euphoria was strongest.

    Fitbit’s slowdown has been mirrored by other companies in the space. The wearables market only grew 3.1% in Q3 of 2016.

    On the flipside, while the debacle of Fitbit — the wearable industry’s iconic company — has been a painful, it’s also been a learning experience. And, it’s not as if the slowdown is unfurling without the wearables market never reaching a respectable size. International Data Corporation estimates were 23 million ‘wearables’ delivered in the third quarter of last year alone.

    Moreover, the fizzling of the market hasn’t turned into a reason to swear off wearables as an investment opportunity… quite the opposite, actually. It’s just now become considerably clearer what consumers want an

  • [By James E. Brumley]

    These are two of the key stumbling blocks Fitbit hit, and the two big stumbling blocks Biotricity Inc (OTCMKTS:BTCY) has completely sidestepped.

    For the unfamiliar, Biotricity is the developer of two different but related wearable, 24/7 heart monitoring technologies. The device called bioflux is for use by caregivers in a clinical setting, remotely transmitting detailed information about the heart’s functioning which can then be analyzed by caregivers. The device known as biolife serves individuals outside of a clinical setting, largely doing the same chore. The advantage of the technology is mobility, without sacrificing accuracy.

  • [By Peter Graham]

    On the other hand, small cap wearables stock Biotricity (OTCQB: BTCY)is a different wearables play as theCompanys mission is to revolutionize chronic care management by developing innovative solutions that bridge the gap between diagnostic care and disease management. A medical technology company, Biotricity is focused on delivering innovative, remote biometric monitoring solutions to the healthcare and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricitys R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The Company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system.

stock market screener: Tobira Therapeutics, Inc.(TBRA)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    Allergan (NYSE: AGN) acquired Akarna Therapeutics global rights to AKN-083 for up-front payment of $50 million. This came just hours after Allergan bought Tobira Therapeutics (NASDAQ: TBRA) for upfront Payment of $28.35 share in cash, up to $49.84 per share in CVRs.

stock market screener: Bonanza Creek Energy, Inc.(BCEI)

Advisors’ Opinion:

  • [By Lisa Levin]

    Bonanza Creek Energy Inc (NYSE: BCEI) shares dropped 53 percent to $0.929 after the company reported that it has entered into a restructuring support agreement with bondholders holding more than $400 million in unsecured debt. The company also disclosed that it will commence its prepackaged bankruptcy case on or before January 5, 2017.

  • [By Dustin Parrett]

    As a service to our readers, we’ve put together a list of 10 cheap oil stocks under $5. Here are the stocks, share prices, and year-to-date (YTD) returns for each:

    Vallourec Sp (OTCMKTS ADR: VLOWY); $1.42; +13.6% YTDIthaca Energy Inc. (TSE: IAE); $1.93; +14.5% YTDSandRidge Permian Trust (NYSE: PER); $3.45; +16.95% YTDGeopark Ltd. (NYSE: GPRK); $5.06; +17.4% YTDGastar Exploration Inc. (NYSEMKT: GST); $1.89; +22.26% YTDAscent Resources Plc. (LON: AST); $2.11; +25.53% YTDErin Energy Corp. (NYSEMKT: ERN); $3.94; +29.1% YTDChesapeake Granite Wash Trust (NYSE: CHKR); $3.25; +38.3% YTDSouthcross Energy Partners LP (NYSE: SXE); $2.27; +68.15% YTDBonanza Creek Energy Inc. (NYSE: BCEI); $2.27; +122.55% YTD

    This list of oil stocks contains some highly speculative plays, so we can’t recommend buying them.

stock market screener: Canadian National Railway Company(CNI)

Advisors’ Opinion:

  • [By Brett Hershman]

    The Swiss bank said it was raising first-quarter estimates on four of the six rails it covers, with updated estimates above consensus on Canadian National Railway (USA) (NYSE: CNI), CSX Corporation (NASDAQ: CSX) and Kansas City Southern (NYSE: KSU), which is seen to show upside against low expectations.

  • [By Monica Gerson]

    Canadian National Railway (USA) (NYSE: CNI) is estimated to post its quarterly earnings at $0.92 per share on revenue of $3.08 billion.

    Container Store Group Inc (NYSE: TCS) is expected to post its quarterly earnings at $0.21 per share on revenue of $230.53 million.